Zejula Adverse Event Report 2018

$19.99

This report includes data from the FDA’s Adverse Events Reports for 2018.  We removed reports where the subject of the report was taking only this drug. This report provides the following fields:

  • ID
  • Patient Summary
  • Patient Gender
  • Patient Age
  • Drug Products
  • Drug Reactions

Description

Zejula (niraparib) is a cancer medicine that interferes with the growth and spread of cancer cells in the body. Zejula is used as a “maintenance” treatment to keep certain types of cancer from coming back. This includes cancers of the ovary, fallopian tube, or peritoneum (the membrane that lines the inside of your abdomen and covers some of your internal organs). Zejula is given after you have received chemotherapy (with cisplatin, oxaliplatin, carboplatin, or similar) and your cancer has responded to that medicine.https://www.drugs.com/zejula.html

Contact US

484-352-2642

What is an Adverse Event Report?

The FDA Adverse Event Reporting System (FAERS) is a database that contains adverse event reports, medication error reports and product quality complaints resulting in adverse events that were submitted to FDA.